Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.35 |
| ▸ | LIPA | P38571 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19169454 | 0.90 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1LIPA | |
| SCHEMBL25095587 | 0.89 | SMN1; SMN2 (0.41) | CHRM3KCNH2SMN1; SMN2 | |
| SCHEMBL25096019 | 0.86 | LIPA (0.34) | LIPA | |
| SCHEMBL25095612 | 0.84 | NCF1 (0.38) | NCF1GNAI3GNAO1GNAI1LIPA | |
| SCHEMBL2558996 | 0.79 | NCF1 (0.43) | NCF1CHRM3ITGB3ITGA2BF2R | |
| SCHEMBL1108993 | 0.79 | NCF1 (0.43) | NCF1CHRM3ITGB3ITGA2BF2R | |
| Hydrochloric Acid SCHEMBL18980447 | 0.78 | NCF1 (0.41) | NCF1GNAI3GNAO1GNAI1CHRM3 | |
| SCHEMBL12309780 | 0.78 | NCF1 (0.41) | NCF1GNAI3GNAO1GNAI1CHRM3 | |
| SCHEMBL12981142 | 0.77 | LIPA (0.39) | LIPAKCNH2CACNA1I | |
| SCHEMBL26723251 | 0.77 | GNAI3 (0.46) | NCF1GNAI3GNAO1GNAI1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9248132-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307515-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-9084795-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8735400-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8563569-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563716-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8530656-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8524901-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8507675-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | NCF1 1399/4885GNAI3 1735/4885GNAO1 2292/4885 |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SLC7A1, SLC7A5, SLC43A1 | NCF1 1498/4885GNAI3 1771/4885GNAO1 3197/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20150307515-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NCF1 989/4885GNAI3 414/4885GNAO1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.